-
U.S. Veterans Study: Fourth Protocol Amendment Submitted to IRB
-
U.S. Veterans Study: Expanded from 16 to 24 Subjects
-
U.S. Veterans Study: Eighth Subject Screened
-
U.S. Veterans Study: Two More Subjects Pass In-Person Screening for U.S. MDMA/PTSD Veterans Study
-
U.S. Veterans Study: First Five Veterans Treated in US MDMA/PTSD Study
-
U.S. Veterans Study: Third Protocol Amendment Submitted to FDA
-
U.S. Veterans Study: Third Protocol Amendment Submitted to IRB
-
U.S. Veterans Study: MDMA/PTSD Study Enrolls First Five Subjects
-
U.S. Veterans Study: First Subject Unblinded in US MDMA/PTSD Veterans Study
-
U.S. Veterans Study: Third and Fourth Subjects Enrolled
-
U.S. Veterans Study: Treatment of First Subjects Begins
-
First Two Subjects in U.S. Veterans Study Scheduled for MDMA Session in January
-
U.S. Veterans Study: Recruitment Begins: First Subject Screened In!
-
U.S. Veterans Study: Second Protocol Amendment Submitted to FDA
-
Veterans of War Study Initiated
-
U.S. Veterans Study: IRB Approves 2nd Amendment
-
U.S. Veterans Study: Second Amendment Submitted to IRB
-
U.S. Veterans Study: DEA Approves License
-
U.S. Veterans Study: Mithoefer Receives DEA License for Phase 1 Psychological Effects
-
U.S. Veterans Study: Recruiting Subjects; Awaiting DEA Review